Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1671
This examiner grants 69% of resolved cases
Yie Chia Lee is an examiner in Tech Center 1600 and Art Unit 1642. The data includes 38 resolved cases with an allowance rate of 68.4 percent. The interview lift is a very high 48.7 percent, indicating that interviews are extremely effective.
The median days to allowance is 1280. This timeline applies to the 38 resolved cases. The 68.4 percent allowance rate suggests a favorable docket, and the 48.7 percent interview lift provides a clear path to improving the odds of success.
Practitioners should be aware of the 1280 median days to allowance. The allowance rate is a solid baseline, and the interview lift is a critical tool for success in Art Unit 1642. With resolved cases, the data suggests that direct communication with the examiner is highly beneficial for navigating the prosecution process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18271206 | MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS | Non-Final OA | The Regents of the University of California |
| 18273395 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES | Non-Final OA | The General Hospital Corporation |
| 17627975 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER | Final Rejection | The General Hospital Corporation |
| 18529691 | TRANSFERRIN RECEPTOR BINDING PROTEINS | Non-Final OA | Sanofi |
| 18684249 | IL-10 Expressing Cells For Enhanced Cancer Immunotherapies | Non-Final OA | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | Final Rejection | CITY OF HOPE |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | Non-Final OA | ARES TRADING S.A. |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | Non-Final OA | Gritstone bio, Inc. |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | Non-Final OA | Viela Bio, Inc. |
| 18274845 | HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF | Non-Final OA | SHANDONG SIMCERE BIOPHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy